HOLX - Hologic, Inc.
(NaN%)
Sell
Moderate Growth but Declining●Stock Price Very High
50%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is -1.39%
Operating Income Growth is 16.0%
Net Income Growth is 44.91%
Earnings Per Share (EPS) Growth is 51.03%
Net Margin is 23.06%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 3.99
Debt Ratio is 0.16
Current Debt to Net Income Ratio is 0.19
Total Debt to Total Assets Ratio is 0.29
Cash Flow is MODERATE
Cash from Operations Growth is 22.45%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Hologic, Inc. (HOLX) - https://www.hologic.com/
driven by our ethos, the science of sure, we’re a diverse, dedicated, creative team that develops, markets and services some of the most innovative and accurate diagnostic imaging systems and surgical products on the planet. while we’re focused and passionate about our work, we never forget that what we’re really doing is giving people greater confidence and peace of mind in their diagnosis—enabling healthier lives, everywhere, every day. connect with us at hologic.com, on facebook at facebook.com/hologicjobs, and on twitter @hologic_jobs.Exchange - NASDAQ
Industry - Irradiation Apparatus Manufacturing
Sector - Manufacturing
CEO - Stephen MacMillan
Employees - 7,797
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.